Invitation – Presentation of Sobi’s Q3 2017 results

On 25 October, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2017.

Financial analysts and...

Read more

Norbert Oppitz joins Sobi™ as new Senior Vice President, Specialty Care

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Norbert Oppitz has been appointed Senior Vice President for the newly established...

Read more

Sobi Receives Approval from the FDA for Once-Daily Dosing Frequency of Orfadin® (nitisinone) for the Treatment of HT-1

First and only nitisinone product approved for once daily use in U.S., designed by Sobi to meet the changing needs of HT-1 patients entering older childhood, adolescence and adulthood.

Read more

Sobi receives approval from the FDA for once-daily dosing frequency of Orfadin® for the treatment of HT-1

Swedish Orphan Biovitrum AB (publ) (Sobi™) has received approval from the U.S. Food and Drug Administration (FDA) for a reduced dosing frequency for...

Read more

New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

As per 31 August 2017, the total number of shares in Swedish Orphan Biovitrum AB (publ) amounts to 272,507,708. All shares are common shares. The...

Read more

Sobi Names Trista Morrison Vice President of Communications in North America

Waltham, Mass., Aug. 16, 2017— Sobi, a leading integrated global biopharmaceutical company dedicated to rare and difficult-to-treat diseases,...

Read more

The board of directors exercises authorization for repurchase of shares to secure the company’s commitments under incentive programme

The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 4 May 2017 resolved – for the purpose of ensuring that the company can fulfil its...

Read more

Sobi™ publishes its report for the second quarter 2017

Read more

Sobi and Bioverativ highlight commitment to improving care for people with haemophilia at ISTH 2017 congress

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI)  and Bioverativ Inc. (NASDAQ: BIVV) today announces that new data from their extended half-life...

Read more

Invitation – Presentation of Sobi’s Q2 2017 results

On 19 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2017.

Financial analysts and media...

Read more

Archive